Navigating FDA's Cancer Drug Review Challenges

This chapter examines a recent series of FDA advisory panel meetings on the review of four cancer drugs, highlighting the effective operations of the FDA's cancer division. It focuses on the contentious issues of data acceptance from Chinese trials and the criteria for meaningful clinical results, particularly in relation to a blood cancer drug reliant on such data.